iBio Inc
IBIO
NASDAQ
Biotechnology
$1.43
USD
+0.03 (+2.14%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $69.55M
Volume 521.3K
Revenue
$300,000
TTM
-20.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-27.61M
TTM
-31.5%
YoY
Operating Cash Flow
$-21.62M
TTM
-39.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 |
YoY Growth | — | +14.3% | — | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 |
Selling, General & Administrative | 3.0 | 2.2 | 2.5 | 0.0 | 5.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.9 | 5.4 | 6.1 | 0.0 | 8.4 |
Operating Income | -4.9 | -5.2 | -6.0 | 0.0 | -8.4 |
EBITDA | -4.8 | -5.3 | -5.8 | 0.0 | -8.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.2 | 0.0 | 0.6 |
Income Before Income Taxes | -4.9 | -5.2 | -5.7 | 0.0 | -7.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.9 | -5.2 | -5.7 | -9.0 | -7.7 |
Consolidated Net Income / Loss | -4.9 | -5.2 | -5.7 | 0.0 | -7.8 |
Net Income Attributable to Common Shareholders | -4.9 | -5.2 | -5.7 | 0.0 | -7.8 |
Basic EPS | -$0.49 | -$0.36 | -$0.11 | $0.00 | -$0.06 |
Diluted EPS | -$0.49 | -$0.36 | -$0.11 | $0.00 | -$0.06 |
Basic Shares Outstanding | 9.9M | 14.4M | 53.0M | 0.0M | 119.6M |
Diluted Shares Outstanding | 9.9M | 14.4M | 53.0M | 0.0M | 119.6M |